Muscle Dysfunction in Patients With Haematological Diseases

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

216 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-10-01

Study Completion Date

2026-05-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

PURPOSE: To evaluate the prevalence and prognostic value of sarcopenia in patients diagnosed with hematological cancer diseases.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Predictors of Malnutrition in Patients With Haematological Cancer

NCT05209321

Malnutrition Lymphoma

COMPLETED

S9910, Collecting and Storing Blood and Bone Marrow Samples From Patients With Hematologic Cancer

NCT00919425

Leukemia Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Neoplasms

COMPLETED

Biology Studies of Hematologic Cancers

NCT00923442

Acute Lymphoblastic Leukemia Myelodysplastic Syndrome (MDS) Non-Hodgkins Lymphoma +2 more

ENROLLING_BY_INVITATION

Prediction of Getting Peripheral Neuropathy in Patients Treated With Bortezomib?

NCT05781425

Chemotherapy-induced Peripheral Neuropathy

COMPLETED

Asian Myeloproliferative Neoplasm (MPN) Registry

NCT05882773

Myeloproliferative Neoplasm Polycythemia Vera Essential Thrombocythemia +5 more

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Some patients diagnosed with malignant hematological diseases are faced with poor prognosis and thus must undergo a demanding course of treatment associated with severe deconditioning potentially leading to worse prognostic outcomes. It is currently not well-described, to what extend patients body composition at the point of diagnoses should be part of standard clinical evaluation in order to optimize therapy-efficacy. Recent findings suggest that pathophysiological alterations in skeletal muscle mass and function can have significant implications for the risk of disease progression and long-term prognosis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hematologic Diseases Acute Myeloid Leukemia Acute Lymphoid Leukemia Myelodysplastic Syndromes Lymphoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort I - Patients newly diagnosed with malignant lymphoma (n=72)

These patients will undergo two assessments: A baseline-assessment prior to treatment for the hematologic cancer disease and a follow-up assessment at 6 months after treatment start

No interventions assigned to this group

Cohort II - Patients newly diagnosed with acute leukaemia (n=72)

These patients will undergo two assessments: A baseline-assessment prior to treatment for the hematologic cancer disease and a follow-up assessment at 6 months after treatment start

No interventions assigned to this group

Cohort III - Patients newly diagnosed with multiple myeloma (n=72)

These patients will undergo two assessments: A baseline-assessment prior to treatment for the hematologic cancer disease and a follow-up assessment at 6 months after treatment start

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

• Patients diagnosed with malignant lymphomas, acute leukaemia and multiple myeloma referred to treatment at the Department of Haematology, Rigshospitalet.